🔴 GT Biopharma is trading 5.25% down in pre-market after $7.45 million private placement raised dilution concerns

GT Biopharma is trading 5.25% down at $7.40 in pre-market as investors continue reacting to its September 15 announcement of a $7.45 million private placement involving convertible preferred stock and warrants, which carries substantial dilution risk.

• Shares previously fell 13.22% on September 16 and 22.61% on September 15.
• Major U.S. indices were higher in pre-market trading; the move appears company-specific.
• Trading remains highly volatile following the recent reverse split and financing developments.